CN101269058B - Spraying agent containing diclofenac acid and uses thereof - Google Patents
Spraying agent containing diclofenac acid and uses thereof Download PDFInfo
- Publication number
- CN101269058B CN101269058B CN2007100882365A CN200710088236A CN101269058B CN 101269058 B CN101269058 B CN 101269058B CN 2007100882365 A CN2007100882365 A CN 2007100882365A CN 200710088236 A CN200710088236 A CN 200710088236A CN 101269058 B CN101269058 B CN 101269058B
- Authority
- CN
- China
- Prior art keywords
- diclofenac
- concentration
- spray
- pain
- azone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a spraying agent containing diclofenac, which consists of diclofenac and adjuvants in pharmacy. The concentration of diclofenac is 1.0 to 2.0 percent (w/v), the spraying agent adopts osthole naphtha and azone as transdermal absorption enhancers for the Chinese medicine compound, the concentration of osthole naphtha is 0.5 to 2.0 percent (w/v) and the concentration of azone is 1.0 percent (w/v). The spraying agent is applied to the preparation of medicines for alleviating pain of urinary and reproductive system caused by virus and bacterial infection as well as pain and anal pain caused by hemorrhoids and after a hemorrhoids operation.
Description
Technical field
The present invention relates to chemical pharmacy field, be specifically related to a kind of spray that contains diclofenac and uses thereof.
Background technology
Diclofenac (diclofenae sodium, claim diclofenac again) be a kind of potent nonsteroidal anti inflammatory, analgesic, effect is stronger 2.0～2.5 times than indomethacin, strong 26～50 times than aspirin, the heating that pain that wide clinical application causes after the various rheumatism of treatment, rheumatoid arthritis, lupus erythematosus, ankylosis rachitis, various operation and a variety of causes cause etc.Because common oral tablet is bigger to the zest of gastric mucosa, and the half-life is short, and only 1.1～1.8h need take medicine 3 every day, can bring a series of untoward reaction to the patient, develop the diclofenac local application preparation that good action easily accepted by the patient again and have the important clinical meaning.
It is more that local use diclofenac is studied, and liniment, patch, emulsifiable paste arranged usually, but be to be used for treatments such as arthritis, athletic injury mostly.The pain that causes for skin infection and hemorrhoid and hemorrhoid postoperative, also have proctalgia, because oral drugs are difficult to reach lesions position, be difficult to the performance curative effect of medication, if heavy dose of the use then can cause serious side reaction.Spray makes medication as the part, compares with solution, liniment, gel, cream, has easy to usely, be difficult for to pollute, and can not produce the advantage that stimulates to the affected part.Use the diclofenac spray, can bring into play curative effect of medication rapidly, make medicine reach valid density rapidly, need not to use auxiliary coating apparatus, bring into play lenitive effect fast and effectively at lesions position.
Application number 95112225.8 discloses a kind of spray containing diclofenac sodium, and this spray is the treatment that is used for oral cavity and pharyngeal inflammation.Its main component comprises diclofenac sodium, propylene glycol, tween 80, sodium sulfite, Oleum menthae and distilled water, and the percentage by weight of each composition is diclofenac sodium 0.5-2, propylene glycol 5-15, tween 80 0-3, glycerol 0.1-0.8, sodium sulfite 0-0.1, distilled water 80-90.
Application number 03123075.X discloses a kind of NSAID of comprising, the topical formulations of diclofenac particularly, be used for alleviating with by herpesvirus, especially the relevant pain/inflammation of infection that causes of herpes simplex virus and varicella zoster virus, this topical formulations is solution, suspension, gel, curdling glue, emulsifiable paste, ointment, lotion or percutaneous plaster.
Use spray to be used to alleviate pain that urinary system and reproductive system cause by virus and bacterial infection and hemorrhoid and hemorrhoid postoperative pain, proctalgia is not seen research report.Use spray to have at these site infections than other dosage form remarkable advantages, easy to use, be difficult for polluting the affected part, also needn't use the adjuvant drug device, avoid stimulating the affected part and the propagation of protecting from infection.
Summary of the invention
The object of the present invention is to provide a kind of diclofenac spray that contains, described spray is made up of the adjuvant on diclofenac and the pharmaceutics, uses Fructus Cnidii volatile oil and azone as the compound Chinese medicine Percutaneous absorption enhancer in this spray.
Another object of the present invention is to provide this spray to alleviate the pain that pain that urinary system and reproductive system cause by virus and bacterial infection and hemorrhoid and hemorrhoid postoperative causes, the application in the proctalgia medicine in preparation.
Spray of the present invention is made up of the adjuvant on diclofenac and the pharmaceutics.
Diclofenac of the present invention can be in diclofenac, diclofenac sodium, the diclofenac potassium a kind of, it is dissolved in the appropriate solvent system.
The concentration of diclofenac is 1.0-2.0% (w/v) in the spray of the present invention, and the concentration of preferred diclofenac is 1.2% (w/v).
Spray of the present invention comprises that the concentration of Chinese medicine Percutaneous absorption enhancer Fructus Cnidii volatile oil is 0.5-2.0% (w/v), and preferred concentration is 1.0% (w/v).
Spray of the present invention comprises that the concentration of Chinese medicine Percutaneous absorption enhancer azone is 1.0% (w/v).
Spray of the present invention also comprises surfactant, and described surfactant is selected from Polyethylene Glycol, tween 80, and sodium lauryl sulphate is preferably tween 80, sodium lauryl sulphate, surfactant concentrations is 1.0-8.0% (w/v).
Spray of the present invention also comprises wetting agent, and described wetting agent is selected from propylene glycol, glycerol, and Polyethylene Glycol, concentration is 0.1-4.0% (w/v).
Spray of the present invention also comprises antiseptic, and described antiseptic is selected from methyl parahydroxybenzoate, ethylparaben, and concentration is 0.1-1.0% (w/v).
Spray of the present invention also comprises Oleum menthae, and concentration is 0.1-0.5% (w/v), adds Oleum menthae to improve the comfort level after using.
Concentration unit of the present invention (w/v) is meant the weight/volume specific concentration, and its corresponding unit is (grams per milliliter).
Spray of the present invention is except that diclofenac and above adjuvant, and all the other are sterile distilled water.
Spray of the present invention is by well known to a person skilled in the art the technology and equipment preparation.
Spray of the present invention is alleviated the pain that pain that urinary system and reproductive system cause by virus and bacterial infection and hemorrhoid and hemorrhoid postoperative causes, the application in the proctalgia medicine as preparation.
Urogenital infections is more common infection, infects usually to be caused by virus and antibacterial, causes that the virus of reproduction, urinary tract infection has herpesvirus and papovavirus usually.Herpesvirus has I type and II herpes simplex virus type, varicella zoster virus etc. usually, causes normally II type herpesvirus and papovavirus that the genitals infects.The antibacterial that causes urinary system, genital system infection is generally pathogen such as gonococcus, non-gonococcus or mycoplasma.In the genital infection treatment, the normally breeding that helps to remove pathogen and suppress pathogen with antiviral agents and antibiotic.But when pathogenic infection,, make the patient be difficult to stand, use the diclofenac spray can obviously suppress the pain that these infection cause, make the patient in therapeutic process, avoid the discomfort that causes because of pain usually with tangible pain.
The typical symptom of hemorrhoid also is a pain, because the affected part is special, the pain in affected part has a strong impact on patient's life, even by operative treatment, after operation, the patient is pain more.When using diclofenac spray of the present invention, be sprayed directly on to the affected part, the equal feels pain of patient disappears or obviously alleviates.Especially for hemorrhoid patients, under pain situation unbearably, use this spray after, pain obviously alleviates.Use this spray behind hemorrhoid operation in three days, operative site does not have the obvious pain sensation, smoothly recovery from illness.Since the difficult painful area that arrives of oral pain alleviating medicine, the local diclofenac spray tool incomparable advantage of using.
Fructus Cnidii is the fruit of samphire cnidium monnieri Cnidium monnieri (L) Cusson.Pharmacological research shows that it has effects such as anti-trichomonal, antifungal, antiviral, antiallergic action.Clinical external can be treated various skin section disease.Volatile oil is one of its main component, wherein mainly contains left-handed pinene, left-handed camphene, isovaleric acid borneol acetate, isoborneol etc.The promoter of exploitation Transdermal absorption from Chinese medicine, often have with low cost, advantage such as toxic and side effects is little.Diclofenac is the potent anthranilic acid anti-inflammatory analgesic of the third generation, and topical application has stronger analgesia and antiinflammatory action.The inventor is through a large amount of experimentatioies, and after discovery Fructus Cnidii volatile oil had good short skin osmosis and azone to share to diclofenac, transdermal enhancing effect obviously strengthened; The bank Study on Effect shows, share azone and can significantly strengthen its bank effect.
The specific embodiment
Below be embodiments of the invention, the embodiment that the present invention provides is in order to further specify the specific embodiments of the invention scheme, rather than is used for limiting protection scope of the present invention.Except as otherwise noted, percent of the present invention is percetage by weight.In addition, concentration unit among the present invention (w/v) is meant the weight/volume specific concentration, and its corresponding unit is (grams per milliliter).
Embodiment 1
The preparation of diclofenac spray
Composition weight
Diclofenac 6g
Fructus Cnidii volatile oil 2.5g
Azone 5g
Oleum menthae 1g
Propylene glycol 10g
Sodium lauryl sulphate 5g
Sterile distilled water adds to 500ml
Method for making:
With diclofenac, Fructus Cnidii volatile oil, azone, Oleum menthae, mixed with propylene glycol, stir, sodium lauryl sulphate adds in the 200ml water, mixes above solvent, adds water to 500ml, and filtering with microporous membrane pours in the automiser spray.
Embodiment 2
The preparation of spray containing diclofenac sodium
Composition quantity
Diclofenac sodium 6g
Fructus Cnidii volatile oil 10g
Azone 5g
Propylene glycol 20g
Tween 80 10g
Methyl parahydroxybenzoate 0.5g
Ethylparaben 0.5g
Oleum menthae 0.5g
Sterile distilled water adds to 500ml
Method for making:
1. propylene glycol is mixed with 200ml water, add diclofenac sodium, Fructus Cnidii volatile oil, azone dissolving.
2. methyl parahydroxybenzoate, ethylparaben, Oleum menthae and tween 80 are added in the 50ml water, be heated to dissolving.
3. above dissolving is mixed, add water to 500ml.
4. above solution filters, and pours in the automiser spray.
Embodiment 3
The preparation of diclofenac potassium solution
Composition quantity
Diclofenac potassium 12g
Fructus Cnidii volatile oil 10g
Azone 10g
Propylene glycol 30g
Oleum menthae 5g
Methyl parahydroxybenzoate 1g
Ethylparaben 1g
Sodium lauryl sulphate 30g
Sterile distilled water adds to 1000ml
Method for making:
1. with diclofenac potassium, Fructus Cnidii volatile oil, azone, Oleum menthae and mixed with propylene glycol dissolving;
2. methyl parahydroxybenzoate, ethylparaben, sodium lauryl sulphate are mixed with 300ml water, be heated to 50 ℃, be stirred to dissolving;
3. above two solution are mixed, stir;
4. add water to 1000ml;
5. filter, pour in the automiser spray.
Embodiment 4
The preparation of diclofenac spray
Composition quantity
Diclofenac 12g
Fructus Cnidii volatile oil 10g
Azone 10g
Oleum menthae 2g
Propylene glycol 30g
Sodium lauryl sulphate 30g
Sterile distilled water adds to 1000ml
Method for making:
1. diclofenac, Fructus Cnidii volatile oil, Oleum menthae are dissolved in propylene glycol;
2. sodium lauryl sulphate, azone are dissolved in the 500ml water;
3. with above two solution mixings;
4. add water to 1000ml;
5. filter, fill is in automiser spray.
Embodiment 5
The preparation of diclofenac spray
Composition quantity
Diclofenac potassium 12g
Fructus Cnidii volatile oil 15g
Azone 10g
Oleum menthae 3g
Propylene glycol 40g
Tween 80 50g
Methyl parahydroxybenzoate 1g
Sterile distilled water adds to 1000ml
Method for making:
1. with diclofenac potassium, Fructus Cnidii volatile oil, azone, Oleum menthae and mixed with propylene glycol dissolving;
2. methyl parahydroxybenzoate, tween 80 are mixed with 300ml water, be heated to 50 ℃, be stirred to dissolving;
3. above two solution are mixed, stir;
4. add water to 1000ml;
5. filter, pour in the automiser spray.
Embodiment 6
The preparation of diclofenac spray
Composition quantity
Diclofenac 20g
Fructus Cnidii volatile oil 15g
Azone 10g
Oleum menthae 3g
Propylene glycol 40g
Tween 80 50g
Methyl parahydroxybenzoate 1g
Sterile distilled water adds to 1000ml
Method for making:
1. with diclofenac potassium, Fructus Cnidii volatile oil, azone, Oleum menthae and mixed with propylene glycol dissolving;
2. methyl parahydroxybenzoate, tween 80 are mixed with 300ml water, be heated to 50 ℃, be stirred to dissolving;
3. above two solution are mixed, stir;
4. add water to 1000ml;
5. filter, pour in the automiser spray.
Embodiment 7
The preparation of spray containing diclofenac sodium
Composition quantity
Diclofenac sodium 2.5g
Fructus Cnidii volatile oil 5g
Azone 5g
Propylene glycol 20g
Tween 80 10g
Methyl parahydroxybenzoate 0.5g
Ethylparaben 0.5g
Oleum menthae 0.5g
Sterile distilled water adds to 500ml
Method for making:
1. propylene glycol is mixed with 200ml water, add diclofenac sodium, Fructus Cnidii volatile oil, azone dissolving;
2. methyl parahydroxybenzoate, ethylparaben, Oleum menthae and tween 80 are added in the 50ml water, be heated to dissolving;
3. above dissolving is mixed, add water to 500ml;
4. above solution filters, and pours into automiser spray.
Comparative example
Because the present invention has determined the suitable content of effective ingredient diclofenac and has combined to select Fructus Cnidii volatile oil and azone as the compound Chinese medicine transdermal enhancer, thereby makes that this medicinal usage is brought into play more fully.Advantage of the present invention can clearly be learnt from following test.
Comparative example 1: mice acetic acid twisting test
Get 50 healthy Kunming kind white mice, be divided into five groups at random, 10 every group, male and female half and half.Press the diclofenac solution of formulated content 2%, 1.2%, 1%, 0.5% concentration of embodiment 1, and be divided into 4 groups.Distilled water is as the blank group.Test preceding 30 minutes mouse web portions and shave hair 1 * 1cm, the blank group is coated with distilled water, and the diclofenac group is coated with variable concentrations diclofenac solution, after 30 fens kinds, every mouse peritoneal is injected the about 0.2ml of 0.6% acetum, observes the number of times that writhing response appears in mice in 15 minutes.
The influence of table 1 pair mice acetic acid twisting reaction
| Grouping | Concentration (%) | Number of animals (n) | Turn round body number of times (X ± SD) | Analgesia percentage rate (%) |
| The blank group | Distilled water | 10 | 24.70±4.41 | 0 |
| The diclofenac group | 2 | 10 | 18.3±5.17 ☆ | 25.91 |
| 1.2 | 10 | 12.6±3.44 * | 48.99 | |
| 1 | 10 | 16.50±16.49 ☆ | 33.20 | |
| 0.5 | 10 | 20.7±13.9 | 16.19 |
The t check, * p＜0.001; ☆ p＜0.01
The variable concentrations medicine of diclofenac group all has inhibitory action to the mouse writhing reaction times, 0.5% concentration group has certain inhibitory action to the mouse writhing reaction times, but there is not significant difference, 1%, 2% concentration group has remarkable inhibitory action to the mouse writhing reaction times, with the blank group significant difference (p＜0.01) is arranged more all, 1.2% concentration group has remarkable inhibitory action to the mouse writhing reaction times, with the blank group utmost point significant difference (p＜0.001) is arranged relatively.
Adopt said method, embodiment 2,3,4,5,6,7 is tested result and above-mentioned basic identical.
Comparative example 2: mice hot plate method test
Thermostatic water-circulator bath case temperature control at 55 ± 0.5 ℃, is placed temperature bath with mice, and licking metapedes with mice is the pain reaction index, and writing down aitiogenic incubation period is normal pain threshold.Select normal pain threshold at 5-30 with 50 of interior Kunming kind female mices, be divided into 5 groups at random, every group 10, make abdominal part warm macerating 10 minutes in 40 ℃ of different medicinal liquids (pressing the diclofenac solution of formulated 0.5%, 1%, 1.2%, 2% concentration of embodiment 2) respectively, normal saline group warm macerating 10 minutes in normal saline.30,60 and 90 fens kinds are surveyed each Mus pain threshold respectively after the medication.
The influence (x ± s n=10) of table 2 pair mice hot plate method threshold of pain reaction
The t check, * p＜0.001; ☆ p＜0.01; △ p＜0.05
Table 2 is that medication front and back threshold of pain difference and normal saline group compare, and 2%, 1% concentration diclofenac group different time has significant difference p＜0.01,1.2% concentration diclofenac group different time that utmost point significant difference p＜0.001 is arranged.
Adopt said method, embodiment 1,3,4,5,6,7 is tested result and above-mentioned basic identical.
Clinical treatment embodiment 1
With female patient 1 example of diclofenac spray treatment herpes infection of the present invention, patient's pudendum infects herpes, shows as the companion's pain of scratching where it itches, with the spraying of this spray subinfection position every days three, symptom is alleviated at once, does not have obvious pain and scratch where it itches to alleviate, use after 4 days, symptom disappears substantially.
Clinical treatment embodiment 2
With diclofenac spray treatment gonorrhea 2 examples of the present invention, patient male, the urethral orifice redness has obvious twinge, behind the oral antibiotic, the local spray that uses, every day 3 times is behind the use spray, at once feel comfortable, no longer twinge after five days, was infected and was cured unbearably the same day.
Clinical implementation example 3
With diclofenac spray treatment syphilis 1 example of the present invention, patient woman, the pudendum redness has skin lesion, pain, and vein uses antibiotic, local use spray containing diclofenac sodium of the present invention, feels pain, painful itching obviously alleviate during the medication, and medication to skin lesion recovers.
Clinical implementation example 4
With diclofenac spray of the present invention treatment hemorrhoid 2 examples, patient man, each 1 example of woman, proctalgia locally uses diclofenac spray of the present invention unbearably during morbidity, spray every day 5 times, after the use all obviously feels pain alleviate, used transference cure 3.
Clinical implementation example 5
With diclofenac spray treatment hemorrhoid 2 examples of the present invention, the patient man, postoperative pain, local use diclofenac spray of the present invention, use repeatedly every day, used 3, and pain disappears substantially between the operating period, after 3 days, the operative site recovery from illness.
Claims (3)
1. spray that contains diclofenac, it is characterized in that described spray is made up of the adjuvant on diclofenac and the pharmaceutics, the concentration of diclofenac is 1.2%g/ml, adjuvant is by Chinese medicine Percutaneous absorption enhancer Fructus Cnidii volatile oil, Chinese medicine Percutaneous absorption enhancer azone, Oleum menthae, propylene glycol, sodium lauryl sulphate and sterile distilled water are formed, wherein the concentration of Fructus Cnidii volatile oil is 0.5-2.0%g/ml, the concentration of azone is 1.0%g/ml, the concentration of Oleum menthae is 0.1-0.5%g/ml, the concentration of propylene glycol is 0.1-4.0%g/ml, and the concentration of sodium lauryl sulphate is 1.0-8.0%g/ml.
2. spray according to claim 1, the concentration that it is characterized in that described Fructus Cnidii volatile oil is 1.0%g/ml.
3. claim 1 or 2 described sprays are alleviated application in the proctalgia medicine that pain that urinary system and reproductive system cause by syphilis, gonorrhea or herpes infection and hemorrhoid and hemorrhoid postoperative causes in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007100882365A CN101269058B (en) | 2007-03-20 | 2007-03-20 | Spraying agent containing diclofenac acid and uses thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007100882365A CN101269058B (en) | 2007-03-20 | 2007-03-20 | Spraying agent containing diclofenac acid and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101269058A CN101269058A (en) | 2008-09-24 |
| CN101269058B true CN101269058B (en) | 2010-09-29 |
Family
ID=40003450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007100882365A Expired - Fee Related CN101269058B (en) | 2007-03-20 | 2007-03-20 | Spraying agent containing diclofenac acid and uses thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101269058B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110092597A1 (en) * | 2009-10-21 | 2011-04-21 | Fangchen Lee | Method for treating herpes virus infection |
| CN103181894B (en) * | 2011-12-30 | 2015-07-15 | 北大方正集团有限公司 | Nabumetone spraying agent and preparation method |
| CN104161751B (en) * | 2014-08-16 | 2015-07-08 | 广州一品红制药有限公司 | Potassium sodium dehydroandrographolide succinate-containing composition and application thereof |
| CN105560734A (en) * | 2016-01-26 | 2016-05-11 | 隋妍蕾 | Cleaning care solution used after haemorrhoid operation and preparation method thereof |
| CN112972385B (en) * | 2021-02-26 | 2022-03-29 | 广东同德药业有限公司 | Inflammation-diminishing and pain-relieving aerosol and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1150541A (en) * | 1995-11-22 | 1997-05-28 | 王树力 | Spray containing diclofenac sodium |
-
2007
- 2007-03-20 CN CN2007100882365A patent/CN101269058B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1150541A (en) * | 1995-11-22 | 1997-05-28 | 王树力 | Spray containing diclofenac sodium |
Non-Patent Citations (8)
| Title |
|---|
| 王晖等.双氯芬酸钠气雾剂的透皮吸收作用.中国医院医学杂志第20卷 第8期.2000,第20卷(第8期),参见第456页摘要，第457页3.讨论. |
| 王晖等.双氯芬酸钠气雾剂的透皮吸收作用.中国医院医学杂志第20卷 第8期.2000,第20卷(第8期),参见第456页摘要,第457页3.讨论. * |
| 王晖等.灰关联聚类法对几种促透剂促透效果的综合评价.中国中药杂志第29卷 第5期.2004,第29卷(第5期),参见第417页摘要. |
| 王晖等.灰关联聚类法对几种促透剂促透效果的综合评价.中国中药杂志第29卷 第5期.2004,第29卷(第5期),参见第417页摘要. * |
| 艾春媚等.蛇床子挥发油对双氯芬酸钠经皮渗透的影响.广东药学第12卷 第1期.2002,第12卷(第1期),参见第43页摘要，第44页3.结果. |
| 艾春媚等.蛇床子挥发油对双氯芬酸钠经皮渗透的影响.广东药学第12卷 第1期.2002,第12卷(第1期),参见第43页摘要,第44页3.结果. * |
| 高允华等.双氯芬酸钠气雾剂的抗炎镇痛作用与毒性研究.泰安医学院学报第22卷 第2期.2001,22(2),参见第85-87页. |
| 高允华等.双氯芬酸钠气雾剂的抗炎镇痛作用与毒性研究.泰安医学院学报第22卷 第2期.2001,22(2),参见第85-87页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101269058A (en) | 2008-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101167811B (en) | External-applied preparation with anti-inflammation, itching-relieving and sterilization function and manufacturing method and application thereof | |
| CN101269058B (en) | Spraying agent containing diclofenac acid and uses thereof | |
| CN103070963B (en) | Traditional Chinese medicine preparation for treating candida albicans infection diseases | |
| WO2014059880A1 (en) | Method for preparation of pomegranate-peel polyphenol gel used to treat gynecological inflammation | |
| CN106692307B (en) | Hydrogel for treating female cervical erosion and preparation method thereof | |
| CN1322895C (en) | Chinese medicinal gel formulation and its preparing process | |
| CN101829130A (en) | Compound resveratrol anti-inflammatory and itching relieving medicament combination and purpose thereof | |
| CN102178731B (en) | Traditional Chinese medicinal nano-cream for treating chronic eczema | |
| CN101601768B (en) | Chinese medicinal composition for treating tinea pedis and scabies and preparation method thereof | |
| CN106619987A (en) | Externally-applied agent for prevention and treatment of pruritus and eczema at female sensitive position | |
| CN101015593A (en) | Gelling agent of gelsemium elegans total alkaloid | |
| CN102988844A (en) | Gynaecological gel and extraction method thereof | |
| CN101053612B (en) | External applied traditional Chinese medicine vagina cleaning agent for curing gynecopathy and vagina cleaning ointment thereof | |
| CN103157050B (en) | Traditional Chinese medicine composition for treating vulvar itching diseases and preparation method thereof | |
| CN100372550C (en) | Three-ingredient traditional Chinese medicine preparation and preparation method thereof | |
| CN104435027A (en) | Pharmaceutical composition delivered in transdermal manner for treating dysmenorrhea, external preparation prepared by using pharmaceutical composition, and preparation method of external preparation | |
| CN100592912C (en) | Externally used compound preparation for treating gynecology disease and method for preparing the same | |
| CN101612203B (en) | Traditional Chinese medicine composition used for treating pointed condyloma and application thereof | |
| CN103585330B (en) | A kind of Chinese medicine composition for cutaneous fungal infection and preparation method thereof | |
| CN101926859B (en) | Chinese medicinal composition | |
| CN103599272B (en) | Chinese herbal lotion for the treatment of gynecological inflammation and preparation method thereof | |
| CN102178732B (en) | Chinese medicine nanoemulsion spraying agent for treating chronic eczema | |
| CN108404094A (en) | A kind of thin network analgesic antiphlogistic bee venom application conditioning cream | |
| CN103816539B (en) | Medicinal composition containing aminolevulinic acid | |
| CN106822714A (en) | A kind of gynaecological gel and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Yangpu Huigu Pharmaceutical Co., Ltd. Assignor: Guo De Contract record no.: 2012990000206 Denomination of invention: Spraying agent containing diclofenac acid and uses thereof Granted publication date: 20100929 License type: Exclusive License Open date: 20080924 Record date: 20120411 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100929 Termination date: 20170320 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |